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A B S T R A C T
Background
Fungal keratitis is a fungal infection of the cornea. It is common in agricultural tropical countries but relatively uncommon in developed
countries. Although there are medications available, their effectiveness is unclear.
Objectives
To examine the effect of different antifungal drugs in the management of fungal keratitis.
Search methods
We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2011, Issue 8),
MEDLINE (January 1950 to August 2011), EMBASE (January 1980 to August 2011), Latin American and Caribbean Literature on
Health Sciences (LILACS) (January 1982 to August 2011), themetaRegister of Controlled Trials (mRCT) (www.controlled-trials.com)
and ClinicalTrials.gov (www.clinicaltrials.gov). There were no date or language restrictions in the electronic searches for trials. The
electronic databases were last searched on 29 August 2011.
Selection criteria
We included all relevant randomised controlled trials (RCTs) on medical therapy for fungal keratitis.
Data collection and analysis
Two review authors selected studies for inclusion into the review, assessed trials for risk of bias and extracted data. Interventions were
compared by the proportions of participants that did not heal after a specific time of therapy. No meta-analysis was performed because
the trials studied different medications with different concentrations.
Main results
We included nine trials in this review; seven conducted in India, one in Bangladesh and one in Egypt. A total of 568 participants
were randomised to the following comparisons: 1% topical itraconazole versus 1% topical itraconazole and oral itraconazole, different
concentrations of silver sulphadiazine versus 1% miconazole, 1% silver sulphadiazine ointment versus 1% miconazole ointment, 2%
econazole versus 5% natamycin, different concentrations of topical chlorhexidine gluconate versus 5% natamycin, 0.2% chlorhexidine
gluconate versus 2.5% natamycin and voriconazole 1% versus natamycin 5%. The included trials were small and of variable quality.
Differences between different regimens were not statistically different, which may reflect the low sample sizes.
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Authors’ conclusions
Based on the trials included in this review, there is no evidence to date that any particular drug, or combination of drugs, is more effective
in the management of fungal keratitis. The trials included in this review were of variable quality and were generally underpowered.
P L A I N L A N G U A G E S U M M A R Y
Medical interventions for fungal infection of the clear front part of the eye (cornea)
Fungal keratitis (fungal infection of the cornea) occurs rarely in higher income countries but is relatively common in lower income
countries. If left untreated the cornea may perforate and may lead to blindness. Although there are a number of medications available, it
is not clear which is the most effective and cost-effective. This review identified nine randomised controlled trials with 568 participants
using different combinations of antifungal drugs. The trials were mainly conducted in India; they were small and of variable quality.
Although there were some observed differences, these could have occurred by chance; none of the studies were large enough to determine
conclusively which agents work best. Further trials with a larger sample size are required in order to answer this important question.
B A C K G R O U N D
Description of the condition
Fungal infections can involve different parts of the eye and perioc-
ular tissues including the lacrimal apparatus, conjunctiva, eyelids
and bony orbit. The most common sites for fungal infections of
the eye involve the cornea and the retina or vitreous (O’ Brien
1997). In the past few decades there have been increased reports of
fungal infections of the eye (O’ Day 1996). These can be mainly
attributed to increased clinical awareness and improved labora-
tory techniques and may also have been caused by widespread use
of corticosteroids, antibiotics, immunosuppressants, chemothera-
peutic drugs and ocular prosthetic devices (O’ Brien 1997).
Epidemiology
Fungal keratitis or keratomycosis is relatively uncommon in de-
veloped countries. There have been no high quality published re-
ports on the incidence rates of the disease. In the United States, it
has been reported that the total number of fungal keratitis cases
annually is approximately 1500 (O’ Day 1996). It is, however,
more common in agricultural and tropical countries. In South
Florida, a nine year survey from 1968 to 1977 revealed that 133
out of 633 cases of corneal ulcers were fungal in origin (Liesegang
1980). In the Philippines, a 25 year survey on central microbial
keratitis revealed a total of 430 cases (Valenton 2000). The most
common etiologic agents are Fusarium, Aspergillus fumigatus and
Aspergillus flavus. In Hyderabad, India, a ten year study on fungal
keratitis showed 1,352 culture proven cases, the most common
etiologic agents included Fusarium,Aspergillus, andCurvularia spp
(Gopinathan 2002).
Themost commonpredisposing factor in fungal keratitis is trauma
associated with plant material. Other risk factors include long-
term corticosteroid use and immuno-compromised patients (O’
Day 1996).
Presentation and diagnosis
Fungal infections almost always present in an insidious manner.
The infection may be recognised within days or weeks and it is
not uncommon for the traumatised epithelium to heal completely
before signs of infection appear. During this latent period the
patient may be asymptomatic. However, within a few days or
weeks the patientmight complain of discomfort, photophobia and
discharge.
During this period, a persistent infiltrate at the site of previous
superficial trauma is present whichmay increase in size and density
in time.The epithelium tends to heal over this inflammatory focus,
although there may be recurrent episodes of epithelial breakdown.
The cornea becomes slightly thickened and ’satellite’ lesions may
develop peripheral to the focal area of infiltration.
If not treated, the inflammatory signs gradually progress causing
permanent breakdown of the epithelium, stromal ulceration, or
formation of descemetocoele (corneal thinning). The cornea may
eventually perforate. Neovascularisation may occur as a result of
inflammation, which may lead to severe scarring of the cornea.
Associated signs indicating the severity of inflammation include
the presence of hypopyon (pus in the anterior chamber) and ciliary
injection. Fungi can invade the deep stroma with great rapidity
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and may gain access to the anterior chamber.
It is important to determine the etiologic agent of the corneal ulcer.
Combined infections with bacteria and fungi or even with multi-
ple fungi might occur. Diagnosis is usually achieved by scraping
material from the base of the ulcer. Some of this material is stained
for fungi and bacteria, the rest is cultured on solid and liquid me-
dia. In severe cases where diagnosis is unclear it may be necessary
to take a larger corneal biopsy.
Description of the intervention
Management of fungal keratitis is mainly by antifungal agents.
Keratoplasty or corneal transplant is usually reserved for acute
management of corneal perforation and for visual rehabilitation
following corneal scarring.
The number of antifungal agents available for therapy is few com-
pared with the number of pathogens capable of infecting the
eye (O’ Brien 1997). Current antifungal agents are divided into
four groups: polyenes, imidazoles, triazoles and fluorinated pyrim-
idines. These drugs can be administered topically, intravenously
or orally. Topical antifungals can cause toxicity such as punctate
keratitis, chemosis recurrent corneal epithelial erosions and con-
junctival injection. Sub-conjunctival injections are quite painful
and ulceration and necrosis of the conjunctival epithelium may
occur.
Current practice in the treatment of fungal keratitis involves the
use of topical antifungal drops such as natamycin and topical am-
photericin B. Newly discovered triazoles such as voriconazole and
posaconazole are also being studied as treatment for fungal ker-
atitis (Galarreta 2007; Tu 2007). In developing countries, where
the incidence of fungal keratitis is higher, the costs and availability
of these polyene drops may be an issue. Hence, various studies
have been performed to validate the effectiveness of chlorhexidine
drops as an inexpensive alternative to the treatment of fungal ker-
atitis (Martin 1996). Combination therapy using several antifun-
gal drugs has been studied. The concomitant use of corticosteroids
and antifungal agents remains controversial (O’ Brien 1997).
In India, due to unavailability and high price of antifungal drugs,
different antiseptic agents were studied in vitro and revealed a good
dose response for chlorhexidine gluconate while povidone iodone
showed a good response in all concentrations (Martin 1996). This
initial study was then followed by a randomised controlled trial
(RCT) to further determine the clinical effectiveness of chlorhex-
idine in confirmed fungal keratitis patients (Rahman 1997).
How the intervention might work
Antifungal medications such as the polyenes work by binding to
the ergosterol in the cell membrane of the fungal organism. Like-
wise, imdazoles affect the plasma membrane formation by affect-
ing the ergosterol throughmicrosomal P-450 enzyme. Pyrimidines
are transformed to fluorouracil in the cell, therefore blocking the
thymidine synthesis (Mabon 1998).
Why it is important to do this review
The gold standard for the treatment of fungal keratitis has not been
identified. Due to the low incidence of the disease it is difficult to
perform large trials, especially in developed countries. A systematic
review of available trials will, therefore, contribute to the evidence
base.
O B J E C T I V E S
To assess the effects of different antifungal drugs in the manage-
ment of fungal keratitis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only RCTs in this review.
Types of participants
We included trials where the participants had fungal keratitis diag-
nosed clinically or microbiologically.We also included trials which
included both people with or without corneal perforation, if sepa-
rate datawere available for those without perforation.We excluded
studies of participants with mixed bacterial and fungal infections.
Types of interventions
We considered studies using various antifungal drugs in the man-
agement of fungal keratitis. This included placebo controlled tri-
als or trials comparing one antifungal agent against another. We
also considered trials comparing antifungal drugs with superficial
keratectomy.
Types of outcome measures
Primary outcomes
1. Clinical improvement: defined as lessening of pain, decrease
in size of infiltrate, disappearance of satellite lesions, rounding
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out of feathery margins of the ulcer, disappearance of hypopyon,
decrease congestion and healing of epithelium defect. Clinical
improvement was assessed on a weekly basis.
2. Clinical cure: defined as healing of the corneal epithelium
with scarring of the cornea. Clinical cure was assessed as absence
of epithelial defect, absence of cellular reaction in the anterior
chamber, presence of corneal vessels and scarring. Clinical cure
was usually expected between six to eight weeks. Time to clinical
cure was a measured outcome.
Secondary outcomes
1. recurrence;
2. therapeutic success based on the initial size of ulcer;
3. cost-effectiveness of treatment;
4. compliance with treatment;
5. complications: number of participants that experienced
complications of fungal keratitis. Complications may include
corneal thinning or descemetocoele formation, corneal
perforation and endophthalmitis;
6. adverse outcomes as reported in trials. These include:
chemosis, punctate keratopathy, recurrent epithelial erosions,
conjunctival injections, ulceration and necrosis of conjunctiva,
hepatotoxicity and renal toxicity;
7. quality of life.
Follow up
We included trials with at least two months follow up.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) 2011, Issue 8, part of The Cochrane Library.
www.thecochranelibrary.com (accessed 29 August 2011), MED-
LINE (January 1950 to August 2011), EMBASE (January 1980
to August 2011), Latin American and Caribbean Literature on
Health Sciences (LILACS) (January 1982 to August 2011),
the metaRegister of Controlled Trials (mRCT) (www.controlled-
trials.com) and ClinicalTrials.gov (www.clinicaltrials.gov). There
were no language or date restrictions in the search for trials. The
electronic databases were last searched on 29 August 2011.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1), MEDLINE (Appendix 2), EMBASE (Appendix
3), LILACS (Appendix 4), mRCT (Appendix 5) and ClinicalTri-
als.gov (Appendix 6).
Searching other resources
We searched the reference lists of identified trial reports to find
additional trials. We contacted investigators and pharmaceutical
companies to identify additional published, unpublished and on-
going studies. We used the Science Citation Index to find studies
that have cited the identified trials. We searched conference ab-
stracts for additional studies but journals were not handsearched.
Data collection and analysis
Selection of studies
Titles and abstracts resulting from the searches were reviewed in-
dependently by two review authors against the inclusion criteria
for the review. We obtained full copies of the studies that definitely
or possibly met the inclusion criteria for further assessment on
whether the paper should be excluded or included. We contacted
trialists for further information in order to determine the relevance
of the study.
Data extraction and management
Two review authors extracted details about the methods, partici-
pants, interventions, outcomes measured and other details of the
included studies and transferred them to the ’Characteristics of
included studies’ table in RevMan (Review Manager 2011). One
review author extracted data using the form developed by the
Cochrane Eyes and Vision Group. A second author compared the
extraction to the original reports. If data were missing or difficult
to determine from a paper, the trialists were approached for clari-
fication and verification. Data were entered into RevMan by one
review author, and the second author checked for errors.
Assessment of risk of bias in included studies
Assessment of the risk of bias of studies was undertaken in accor-
dance with the methods given in Chapter 8 the Cochrane Hand-
book for Systematic Reviews of Intervention (Higgins 2011). Two re-
view authors independently assessed the studies and disagreements
between authors were resolved by discussion. Four bias domains
were considered: selection bias, performance bias, detection bias
and attrition bias. Assessment was based on the following ques-
tions:
1. Selection bias (random sequence generation and allocation
concealment): was the sequence of allocation of participants to
groups randomly generated and concealed until after treatments
were allocated?
2. Performance bias (masking of participants and researchers):
were the recipients of care unaware of their assigned treatment?
Were persons providing care unaware of the assigned treatment?
3. Detection bias: were persons assessing outcome unaware of
the assigned treatment?
4. Attrition bias: were rates of follow up similar in the
comparison groups? Was the analysis ’intention-to-treat’ (were all
participants analysed as randomised)?
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We assessed each parameter as ’low risk of bias’, ’high risk of bias’
or unclear. We contacted trialists for clarification of any parameter
graded as unclear. In the protocol we planned to conduct a sen-
sitivity analysis excluding studies at high risk of bias: the current
review does not include any meta-analysis so that was not done.
Data synthesis
We presented summary measures for dichotomous data as relative
risk ratios. For continuous data we calculated the weighted mean
difference. We presented the point estimate and confidence inter-
vals with a 95% confidence interval for individual results.
We did not pool data from the individual trials but in the protocol
we specified that we would use the fixed-effect model if the total
number of trials in the comparison was three or less provided
that heterogeneity had not been detected either statistically or by
review. If the number of trials was more than three we planned to
use the random-effects model.
Sensitivity analysis
We did not conduct sensitivity analysis as we did not do a meta-
analysis. If possible we will do so for future updates so that we
can assess how robust the review results were to key decisions and
assumptions that were made during the review. Analysis of data
will be repeated with the following adjustments:
1. exclusion of studies at greater risk of bias;
2. exclusion of unpublished studies;
3. changing inclusion criteria such as lowering methodological
cut-off points.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The electronic searches resulted in 471 reports of possible medi-
cal interventions for fungal keratitis. Twenty three abstracts were
retrieved in full for further assessment. Six RCTs were identified
for inclusion (Agarwal 2001; Mohan 1987; Mohan 1988; Prajna
2003; Rahman 1997; Rahman 1998).
An updated search was done in January 2007 and Februrary 2010.
The searches yielded a total 206 and 23 references respectively. The
Trials Search Co-ordinator (TSC) scanned the search results for
both updates and removed any references which were not relevant
to the scope of the review. The update searches did not identify
any references which met the inclusion criteria for the review.
A further update search was done in August 2011. After dedu-
plication the search identified a total of 50 references. The TSC
scanned the search results and removed 41 references which were
not relevant to the scope of the review. We reviewed the remain-
ing nine references of which five were published reports of stud-
ies and four were reports of ongoing studies. We assessed the five
published reports of studies for potential inclusion in the review.
We obtained full-text copies of three studies and have included
them in the review (Arora 2011; Mahdy 2010; Prajna 2010). The
remaining two reports did not meet the inclusion criteria. Of the
four reports of ongoing studies trial NCT00557362 is the initial
report of the published paper by Prajna 2010. The three other
reports of ongoing studies are relevant to the review and have been
added to the studies awaiting assessment section and the results
will be included in the review when the studies have been com-
pleted (NCT00996736; NCT00997035; NCT00516399).
Contact with first authors of identified trials and searching the
reference lists of these studies failed to identify any additional
trials. We also approached pharmaceutical companies producing
antifungal agents but therewas no information on additional trials.
Included studies
See the ’Characteristics of included studies’ table for additional
details for included studies.
Size of studies
The nine included trials randomised a total of 568 participants:
Agarwal 2001 (54 participants); Arora 2011 (30); Mahdy 2010
(48); Mohan 1987 (30) Mohan 1988 (40); Prajna 2003 (116);
Prajna 2010 (120); Rahman 1997 (60); Rahman 1998 (70).
Types of participants
Sevenof the trialswere conducted in Indiawith one trial conducted
in Bangladesh (Rahman 1998) and one trial in Egypt (Mahdy
2010). Trials included people with awide range of ages, from seven
to 84 years of age, although in general the patient populations were
younger rather than older, with average ages less than 50 years.
The majority of the participants were male; the percentage male
ranged from 64% to 78% in the included trials.
The majority of the trials included participants with microbiolog-
ical evidence of fungal keratitis. Two trials (Agarwal 2001; Mahdy
2010) included participants based on a clinical definition only.
Types of interventions
Table 1 summarises the antifungals studied. The trials were het-
erogenous in terms of types of antifungals studied. Seven antifun-
gal drugs in different preparations and routes of administration
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were used. Agarwal 2001 compared topical and systemic itracona-
zole versus topical itraconazole. Mohan 1987 compared 0.5% and
1% silver sulphadiazine in ointment form to 1%miconazole oint-
ment whileMohan 1988 compared 1% silver sulphadiazine versus
1% miconazole ointment. Prajna 2003 compared 2% econazole
and 5% natamycin in topical preparations. Rahman 1997 com-
pared different concentrations of chlorhexidine gluconate versus
5% natamycin while Rahman 1998 compared 0.2% chlorhexi-
dine gluconate versus 2.5% natamycin. Arora 2011 and Prajna
2010 compared topical voriconazole 1% with natamycin 5% and
Mahdy 2010 compared amphotericin B combined with subcon-
junctival injection of fluconazole with amphotericin B alone.
Agarwal 2001, Mohan 1987 and Mohan 1988 were cross-over
trials. Data on the first treatment was used for the review.
Types of outcome measures
The majority of trials considered healing of ulcer, or time taken
for ulcer to heal, as the primary outcome. Prajna 2010 specified
visual acuity as the primary outcome. Follow-up varied: Rahman
1997 andRahman 1998 considered healing of ulcer at three weeks;
Mohan 1987 and Prajna 2003 considered healing at four weeks;
Mohan 1988 did not specify a cut-off time but noted healing of
ulcers within two to four weeks; Agarwal 2001 considered healing
of ulcer at six weeks as primary outcome; Arora 2011 followed up
for a minimum of 10 weeks, or until the ulcer healed; Prajna 2010
specified the main outcome at three months; and Mahdy 2010
also followed up for three months. The trials noted a healed ulcer
based on slit lamp findings such as disappearance of hypopyon
and circumoral congestion, absence of fluorescein staining. Local
and systemic adverse reactions were noted by some trials.
Excluded studies
See the ’Characteristics of excluded studies’ table for details.
Risk of bias in included studies
See Figure 1 and Figure 2.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
7Medical interventions for fungal keratitis (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Only three trials reported adequate methods of sequence gener-
ation and allocation concealment (Prajna 2010; Rahman 1997;
Rahman 1998).
Blinding
Masking of participants was not always possible. Only Mohan
1988 and Prajna 2010 reported adequate masking of participants,
personnel and outcome assessment.
Incomplete outcome data
Arora 2011,Mohan1987;Mohan 1988, Prajna 2010 andRahman
1997 had reasonably complete data. In the other studies, attrition
bias was considered to be possible.
Selective reporting
Selective reporting was not considered to be a major problem in
the included trials but it was not always possible to assess this
adequately.
Other potential sources of bias
Trials byMohan 1987,Mohan 1988 andAgarwal 2001were cross-
over trials which can be a potential source of bias.
Effects of interventions
Treatment failure
1. Topical itraconazole versus topical and systemic itraconazole
The combination of topical (1%) and oral intraconazole (100 mg
twice daily for three weeks) did not appear to confer any additional
advantage to itraconazole alone (Agarwal 2001) with a relative risk
(RR) of 1.0; 95% confidence internal (CI) 0.37 to 2.71.
2. Silver sulphadiazine versus miconazole
The results of two studies by the same author (Mohan 1987;
Mohan 1988) indicated that silver sulphadiazine was more effec-
tive than miconazole, however, the confidence intervals were wide
and the results were also compatible with a greater efficacy of mi-
conazole. Mohan 1987: silver sulphadiazine (0.5% and 1%) com-
pared to 1% miconazole gave a RR (of failure, i.e. not healing
of ulcer) of 0.63; 95% CI 0.21 to 1.83. Mohan 1988 1% silver
sulphadiazine ointment compared to 1% miconazole ointment:
RR 0.44; 95% CI 0.16 to 1.21. The pooled estimate of these two
trials was 0.51 (95% CI 0.25, 1.07) (Analysis 1.1).
3. Econazole versus natamycin
In Prajna 2003, there appeared to be little difference in the effects
of econazole and natamycin: RR 0.99: 95% CI 0.8 to 1.21.
4. Chlorhexidine gluconate versus natamycin
In two trials by the same investigators (Rahman 1997; Rahman
1998) there was some evidence for a favourable effect of chlorhex-
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idine compared to natamycin in response at five days (Analysis
2.1), however, the results on healing of the ulcer at 21 days was
less conclusive (Analysis 2.2).
5. Voriconazole versus natamycin
Arora 2011 and Prajna 2010 found no evidence for any difference
between these two antifungal agents. However, Arora 2011 was
rather small and it was not possible to combine the results of these
studies because of differences in outcomes presented. Prajna 2010
found that people treated with voriconazole had a 1 line better best
correct visual acuity compared to people treated with natamycin
at three months, however, this difference was not statistically sig-
nificant.
6. Amphotericin B combined with fluconazole (subconjunctival in-
jection)
Mahdy 2010 found a higher proportion of ulcers healed with
combination treatment (amphotericin B and fluconazole) (83%)
compared to amphotericin alone (67%), however. this study was
considered to be at relatively high risk of bias (Figure 1).
Adverse reactions
Mild side effects were noted in topical itraconazole, which in-
cluded:
1. corneal oedema in two cases;
2. increased intraocular pressure in two cases; and
3. prolonged congestion in four cases.
On the other hand, no significant side effects were reported in
patients with oral itraconazole.
Mild local allergic reactions were observed in three eyes using silver
sulphadiazine ointment as reported in Mohan 1988.
Prajna 2003 did not elaborate on the ocular and systemic ad-
verse reactions due to 2% econazole and 5% natamycin. No sys-
tematic adverse effects were recorded in Prajna 2010. There were
nine corneal perforations in the natamycin group and 10 in the
voriconazole group. No adverse reactions to study medications
were noted in Arora 2011. In Mahdy 2010 two cases of subcon-
junctival haemorrhage associatedwith the injection sitewere noted
but no conjunctival necrosis.
There was no report of significant systemic or ocular adverse re-
actions from both chlorhexidine gluconate and natamycin. A case
of temporary punctate epitheliopathy was observed in one partici-
pant receiving chlorhexidine gluconate. This was attributed to in-
creased frequency of application of the drops.No early cataract for-
mation was observed at six months to one year after treatment for
participants exposed to chlorhexidine gluconate and natamycin.
D I S C U S S I O N
This systematic review aimed to provide a critical, quantitative
overview of previous clinical research and to yield, where possi-
ble, summary effect measures with increased statistical power by
combining multiple small clinical trials. The current review in-
cludes nine trials comparing different antifungal drugs in topical
drops, ointment and oral preparations for the treatment of fun-
gal keratitis. All trials were done in developing countries since the
incidence is higher compared to developed countries such as the
United States. There are still no large multicentre randomised tri-
als on the treatment of fungal keratitis.
Seven antifungal agents, namely: voriconazole, econazole, itra-
conazole,miconazole, natamycin, chlorhexidine gluconate and sil-
ver sulphadiazine were studied. The latter two are not part of the
conventional drugs which act on the hyphal cell membranes. The
use of alternative drugs such as chlorhexidine gluconate and sil-
ver sulphadiazine may indicate that conventional drugs are not al-
ways available, are expensive and ineffective. Since fungal keratitis
is more common in developing countries the use of inexpensive
alternative drugs is promising. In addition, a less financial incen-
tive has been offered to pharmaceutical companies to invest in
the development of ocular antifungal agents. The only commer-
cially available antifungal drug in the United States in ophthalmic
form is natamycin (Natacyn 5% by Alcon Laboratories). In Asia
and Africa, Natacyn is given as a service drug but with limited
availability. In India, topical natamycin is manufactured by a lo-
cal pharmaceutical company, however, no clinical trials have been
done on this drug.
Three pairs of trials had the same primary author. One pair com-
pared different concentrations of the drug chlorhexidine gluconate
with natamycin, while the other pair compared different concen-
trations of silver sulphadiazine with miconazole. Succeeding stud-
ies may have based the concentration of the study drug from the
previous trials.The other pair considered different formulations.
Although natamycin was used as the control drug in four of the
six trials, it is not yet considered as the gold standard for treatment
for fungal ulcer because of low success rate.
Comparing treatment effects of all the drug preparations studied,
silver sulphadiazine ointment has the lowest proportion of par-
ticipants with treatment failure followed by itraconazole in both
treatment arms, miconazole ointment, chlorhexidine gluconate,
econazole. The drugwith the highest failure proportionwith failed
ulcer was natamycin (2.5% and 5%). However, these compar-
isons between treatment arms of different studies do not represent
randomised comparisons (it is effectively an observational study),
thus these differences may reflect differences in the different pop-
ulations studied.
Summary of main results
Based on the nine trials included in this review, there is no evi-
dence that any particular drug, or combination of drugs, is more
effective in themanagement of fungal keratitis. However, the trials
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included in this review were of variable quality and were generally
underpowered.
Overall completeness and applicability of
evidence
The evidence supporting the treatment of fungal keratitis appears
to be weak. Only nine trials of variable quality were identified.
The trials considered different preparations and comparisons and
so it was not possible usefully to pool the data.
Treatment regimens such as amphotericin B and other new drugs
such as voriconazole have not yet been studied in a large scale
manner.
Quality of the evidence
The review provides weak evidence for the drugs used in manage-
ment of fungal keratitis. Nine trials with 568 participants have
been included using different antifungal medications. There was
no consistent drug of comparison (control). We did not combine
results since the drugs used were different.
Potential biases in the review process
An exhaustive search on the trials was done. However, there are
few RCTs on fungal keratitis since the disease is rare in developed
countries. Since fungal keratitis ismore often studied indeveloping
countries, unpublished reports might have been excluded.
Agreements and disagreements with other
studies or reviews
Most of the trials on management of fungal keratitis gathered
during the literature search are case series. Only the RCTs were
included in the review.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The first line of treatment in fungal keratitis is topical antifungal
agents. Although it is prudent to wait for culture and sensitivity
results before instituting medical therapy, fungi do not grow as
fast as bacteria even under well-controlled conditions. Thus, anti-
fungal agents are administered promptly once fungal elements are
seen on microbiology examination.
Current antifungal agents used in the treatment of fungal kerati-
tis in the RCTs are varied. Furthermore, the different studies are
weak, owing to their small sample size. The results of these studies
also did not show a significant difference among the heterogenous
interventions. There is little evidence to support the use of any
particular drug, or combination of drugs.
Implications for research
There is a need for future multicentre RCTs with a large sample
size and the treatment given can be any of the interventions in
the previous RCTs. Since the price of these drugs are likewise
prohibitive to patients in developing nations, cost-effectiveness of
these drugs should also be examined. The search for a cheaper
and more effective treatment alternative to what has already been
proposed still continues.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Agarwal 2001
Methods Randomised controlled cross-over trial
Masking: It is impossible to be masked due to systemic intervention compared to topical
only
Participants Setting: Calcutta, India
54 patients divided into 2 groups. Group I comprised new patients and Group II com-
prised patients who had been previously treated with agents. No inclusion and exclusion
criteria elaborated. Clinically suspected cases were included
Male (69%), 50% aged 21 to 40 years
No participants were reported to be excluded or dropped in the study. Patients were
followed up for 6 months
Interventions 1% topical itraconazole versus 1% topical itraconazole and 100 mg BID for 3 weeks
oral itraconazole. Topical itraconazole was prepared by mixing 100 mg of itraconazole
powder with 100 mL artificial tear solution. Oral itraconazole was discontinued after 3
weeks while topical itraconazole was continued for 6 weeks after resolution of keratitis
Outcomes Main outcome was healing of corneal ulcer, within 6 weeks. Favourable response was
further graded based on corneal opacity and visual acuity. Other parameters included
residual corneal opacity, best corrected visual acuity and rate of improvement. Side effects
such as oedema, glaucoma and congestion were also reported if present
Notes This is a preliminary study. Aspergillus was common etiology found. Fusarium was not
responsive to itraconazole
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The patients were divided into two groups”
on the basis of new and untreated patients
but no other information is given
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not reported but treatments different
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not reported but treatments different
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Agarwal 2001 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not possible to assess
Selective reporting (reporting bias) Unclear risk Not possible to assess
Arora 2011
Methods Randomised controlled trial
Participants Setting: Tertiary care hospital in India
30 people with fungal keratitis, confirmed by microbiology
Predominantly male (group A 67% male, group B 73% male). Average age 37.9 (15.1)
years in group A and 48.5 (13.5) years in group B
Interventions 5% natamycin versus 1% voriconazole. Patients were followed up for a minimum of 10
weeks, or until complete resolution of the ulcer
Outcomes Resolution of the ulcer and visual acuity
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “This study was randomized, double-masked, interven-
tional, pilot study of patients with fungal keratitis”. Meth-
ods, first paragraph
“They were randomly divided into two groups of 15 patients
using the lottery methods”. Methods, first paragraph
Allocation concealment (selection bias) Unclear risk “Double masking of treatment assignment was achieved by
dispensing the medications in identical opaque bottles and
by having the ward nurses wipe any white residue from the
patient’s eye prior to study assessment as natamycin is deliv-
ered via suspension, whereas VRC is in solution”. Methods,
first paragraph
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Double masking of treatment assignment was achieved by
dispensing the medications in identical opaque bottles and
by having the ward nurses wipe any white residue from the
patient’s eye prior to study assessment as natamycin is deliv-
ered via suspension, whereas VRC is in solution”. Methods,
first paragraph
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double masking of treatment assignment was achieved by
dispensing the medications in identical opaque bottles and
by having the ward nurses wipe any white residue from the
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Arora 2011 (Continued)
patient’s eye prior to study assessment as natamycin is deliv-
ered via suspension, whereas VRC is in solution”. Methods,
first paragraph
Incomplete outcome data (attrition bias)
All outcomes
Low risk There were no reported drop outs in both treatment and
control groups. Follow up ranged from 10 days to 60
days
Selective reporting (reporting bias) Unclear risk The primary outcome was defined as the “time taken for
the complete resolution of the ulcer”. Methods, last para-
graph
Various other outcomes reported e.g., visual acuity and
mean size of the ulcer
Mahdy 2010
Methods Randomised controlled trial
Participants Setting: hospital in Egypt
48 people with clinical signs of fungal keratitis
Male (65%), aged 15 to 64 years, average age 44 years
Interventions Topical amphotericin B (0.5 mg/ml) and subconjunctival fluconazole (2mg/ml) com-
pared to topical amphotericin B alone
Outcomes Healing of corneal ulcer. Follow-up 3 months
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The study is a prospective, randomized one,..” Page 282
“Eyes with similar clinical and laboratory findingswere clas-
sified into 2 groups of treatment.” Page 282
Allocation concealment (selection bias) High risk No description on method of allocation concealment
however the study groups were exactly matched for fun-
gal species (table 2) which is unlikely on this number of
patients if the allocation was truly random
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants were not masked
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Mahdy 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome assessors were not masked
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not reported
Selective reporting (reporting bias) Unclear risk Difficult to judge from report
Mohan 1987
Methods Randomised controlled cross-over trial
Six ulcers had no response. No significant systemic and ocular side effects noted
Participants Setting: New Delhi, India
Included patients were positive for KOH smear
30 patients were included; 10 for 0.5% silver sulphadiazine, 10 for 1% silver sulphadi-
azine and 10 for 1% miconazole
Age and sex not reported
Interventions 0.5% topical silver sulphadiazine, 1% topical silver sulphadiazine and 1% topical mi-
conazole all in ointment form
Outcomes Main outcome was healing described as absence of fluorescein staining, disappearance
of hypopyon, lack of circumcorneal congestion and negative culture
Notes Silver sulphadiazine had 100% effectivity in Fusarium ulcers
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The cases were divided into 3 treatment
groups […] on a random basis” Page 573
Allocation concealment (selection bias) Low risk “The drugs […were] coded by the Ocular
Pharmacology Laboratory” Page 573
“At the end of the trial, the code was broken
and the result analyzed” Page 573
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Each patient was given a coded antifungal
ointment tube of 5g to be applied 5 times a
day and the entire study was conducted in a
double blind manner” Page 573
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “The drugs […were] coded by the Ocular
Pharmacology Laboratory” Page 573
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Mohan 1987 (Continued)
“Each patient was given a coded antifungal
ointment tube of 5g to be applied 5 times a
day and the entire study was conducted in a
double blind manner” Page 573
“At the end of the trial, the code was broken
and the result analyzed” Page 573
Incomplete outcome data (attrition bias)
All outcomes
Low risk “There was no fallout from this study on ac-
count of poor patient compliance” Page 573
Selective reporting (reporting bias) Low risk Probably not a problem as they reported
ulcers responding to treatment
Mohan 1988
Methods Randomised controlled double masked cross-over trial
Follow-up not stated but rather average healing time. Forty smear positive patients (20
each) were analysed. No reported cases of lost to follow-up
Participants Setting: New Delhi, India
Included patients were smear positive. No exclusion criteria given
Male (78%), aged 14 to 68 years
Interventions 1% topical silver sulphadiazine versus 1% miconazole both in ointment preparations.
In absence of improvement in one week, participants were switched to other drug.
Interventions were continued for 2 more weeks after healing. Mean days of resolution
of ulcers was 20.7 for miconazole and 23.9 for silver sulphadiazine
Outcomes Healing is described as disappearance of hypopyon and circumcorneal congestion, ab-
sence of staining and a negative report for culture. Local and systemic adverse effects
were noted
Notes Ulcers were graded based on size and hypopyon. On cross-over, miconazole resistant
fusarium ulcers were healed by silver sulphadiazine. Aspergillus was the most common
etiologic agent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “The patients were assigned alternately to
each of two groups” Page 192
Allocation concealment (selection bias) High risk Not reported but as sequence was alternate
allocation we have assumed that conceal-
ment was not possible
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Mohan 1988 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “The two ointments were coded and supplied
to the patients in identical packings.” Page
192/193
“At the end of the study the code was broken
and the results analyzed” Page 193
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “At the end of the study the code was broken
and the results analyzed” Page 193
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Three patients (two on miconazole and one
on silver sulphadiazine) developed local al-
lergic reactions, possibly due to the ointment
base. They were excluded from further analy-
sis and do not form part of the studymaterial”
Page 193
Low risk of bias recordedhere as this is quite
a low proportion with missing data andwas
distributed between the two groups
Selective reporting (reporting bias) Low risk Probably not a problem as reported ulcers
responding to treatment
Prajna 2003
Methods Randomised controlled trial
2 patients were lost to follow up in both groups
Participants Setting: Aravind, India
Included patients with smear and culture positive for fungal infection were included.
Other inclusion criteria includes size of ulcer at least 2 mm2 and not more than 60 mm2.
Excluded were patients who did not consent to study and did not meet inclusion criteria.
116 participants included
Male (64%), age range 7 to 84 years, average age 37 (13.8) years
Interventions 2% econazole and 5% natamycin in topical eye drops/ suspension. Atropine sulfate
ointment were given to both groups
Outcomes Main outcome is healed ulcer defined as completely healed epithelial defect with no
fluorescein staining, non progression of stromal infiltration
Notes Follow duration was 4 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
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Prajna 2003 (Continued)
Random sequence generation (selection
bias)
Unclear risk “…subjects were randomized to receive ei-
ther…” Page 1235
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Since natamycin is available as a suspension,
and precipitates in the corneal tissue, it was
not possible to mask the investigator to the
drugs used on subsequent visits.” Page 1235
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Since natamycin is available as a suspension,
and precipitates in the corneal tissue, it was
not possible to mask the investigator to the
drugs used on subsequent visits.” Page 1235
Incomplete outcome data (attrition bias)
All outcomes
High risk “Four of the 116 patients randomized at base-
line did not return for further follow-up (Fig
1) and were dropped from the study.” Page
1236
However this contradicts figure 1 where 5
people lost to follow-up by week 4. Also
large numbers of people “exited” the study
due to clinical worsening or reaction to
drops. By week 4 25/61 in the econazole
group and 22/55 of natamycin group re-
mained in the study
Selective reporting (reporting bias) Low risk Reported “time to cure” and no indication
of any unreported variables
Prajna 2010
Methods Multicentre double masked randomised controlled trial
Participants 120 people with fungal keratitis at Aravind Eye Hospital, India
Male (66%), average age in each of four study groups ranged from 45 to 50 years
Interventions Topical natamycin versus topical voriconazole
Outcomes Best spectacle-corrected visual acuity at 3 months. Other outcomes included scar size,
perforations
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Prajna 2010 (Continued)
Random sequence generation (selection
bias)
Low risk “This study was a randomized, double-
masked, clinical trial of patients with fungal
corneal ulcers.” Page 673
“Patients were block randomized in groups
of 4 (using the statistical package R; http: //
www.r-project.org) by T.P.” Page 673
Allocation concealment (selection bias) Low risk “Double-masking of treatment assignment
was achieved by dispensing the medications
in identical opaque bottles and by having the
ward nurses wipe any white residue from the
patient’s eye prior to study assessment. In addi-
tion, patients were no longer receiving treat-
ment at 3 months, the time that the primary
outcome of final visual acuity was measured.
Only the biostatisticians responsible for the
randomization coding and the study pharma-
cist were unmasked.” Page 673
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-masking of treatment assignment
was achieved by dispensing the medications
in identical opaque bottles and by having the
ward nurses wipe any white residue from the
patient’s eye prior to study assessment. In addi-
tion, patients were no longer receiving treat-
ment at 3 months, the time that the primary
outcome of final visual acuity was measured.
Only the biostatisticians responsible for the
randomization coding and the study pharma-
cist were unmasked.” Page 673
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Double-masking of treatment assignment
was achieved by dispensing the medications
in identical opaque bottles and by having the
ward nurses wipe any white residue from the
patient’s eye prior to study assessment. In addi-
tion, patients were no longer receiving treat-
ment at 3 months, the time that the primary
outcome of final visual acuity was measured.
Only the biostatisticians responsible for the
randomization coding and the study pharma-
cist were unmasked.” Page 673
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Efficacy endpoints were analyzed on an in-
tent-to-treat basis for all randomized patients
enrolled in the study. The primary analysis in-
cluded the actual 3-month data when avail-
able and last observation carried forward for
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Prajna 2010 (Continued)
missing values.” Page 674
“Sensitivity analyses were also performed in
which we separately (1) assigned surgical pa-
tients the value 1.7 instead of 1.9, (2) assigned
patients with perforation (but no surgery) the
value 1.7 or 1.9 (instead of using last ob-
servation carried forward), (3) analyzed only
patients with complete followup, or (4) used
multiple imputation (recursive random par-
titioning-based hot deck method)” Page 674
11/120 lost to follow-up but evenly dis-
tributed across study groups 2/2/4/3
Selective reporting (reporting bias) Low risk “The primary efficacy endpoint was BSCVA
at 3 months in the study eye, using a lin-
ear regression model with 3-month logMAR
BSCVA as the outcome variable and treat-
ment arm (voriconazole vs natamycin) and
enrollment logMARBSCVA and scraping (yes
or no) as covariates.” Page 674
“Other
prespecified endpoints included BSCVA at 3
weeks, adjusting for enrollment BSCVA, and
infiltrate/scar size at 3 weeks and 3 months,
adjusting for enrollment infiltrate/scar size.”
Page 674
Rahman 1997
Methods Randomised controlled double masked trial. Two patients were lost to follow-up after
randomisation for unknown reasons. Follow-up was at least 21 days
Participants Setting: Aravind Eye Hospital in Madurai, India
Included patients were smear positive for hyphal elements
Excluded were patients with only one eye, patients with diabetes mellitus, polymicrobial
infections, those unwilling to participate fully or attend for follow up, children under 1
year of age and perforated ulcers
Male (76%), aged 50 years and above (33%)
Interventions Concentrationof chlorhexidine gluconatewas varied (0.05%, 0.1%and 0.2%) compared
to 5% natamycin. Rescue drugs is given if there is no improvement at 5 days
Outcomes Outcome measures were response at 5 days, cure by day 21 and toxicity. Favorable
response was defined as relief of symptoms, improvement of at least one the following
signs of inflammation. Healing at 21 days characterised as intact epithelium, with or
without scar formation, but no perforation, anterior staphyloma, no adherent leukoma,
no fluorescein staining, no hypopyon and improvement of vision or vision no worse than
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Rahman 1997 (Continued)
baseline
Notes Data was also stratified based on severity of ulcers. Twelve patients with severe ulcers
were excluded in the analysis of outcome at 21 days since only 1 (from chlorhexidine
gluconate 0.05%) had favourable response. Fusarium was the most common etiologic
agent cultured
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization was computer generated
by statisticians at Aravind, using the one-sam-
ple run test.” Page 143
Allocation concealment (selection bias) Low risk “… 60 consecutive patients were randomly
allocated in a double-masked fashion..” Page
142
“The bottles were prepared and labelled only
with the randomized numbers by the Aravind
executive staff” Page 143
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “… 60 consecutive patients were randomly
allocated in a double-masked fashion..”
Page 142
“The bottles were prepared and labelled only
with the randomized numbers by the Aravind
executive staff” Page 143
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “… 60 consecutive patients were randomly
allocated in a double-masked fashion..” Page
142
“The bottles were prepared and labelled only
with the randomized numbers by the Aravind
executive staff” Page 143
But for “treatment failures” the code was
broken on day 5 so presumably all assess-
ments after that date were unmasked
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Two patients were lost to follow-up, so that
58 patients were left in the study” Page 144
Selective reporting (reporting bias) Unclear risk A number of different outcome measures
reported and no indication as to whether
these were all outcomes on which data col-
lected
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Rahman 1998
Methods Randomised controlled trial with follow up at least 6 months. Seventy one patients were
eligible but one was excluded because it was a mixed infection. Seventy patients were
randomised to two arms 35 each. Six patients (3 on each arms) were dropped due to
incomplete follow-up. Only 32 were assessed at 21 days
Participants Setting: Bangladesh
Included patients where smear positive for hyphal elements. Excluded were patients with
only one eye, patients with diabetes mellitus, polymicrobial infections, those unwilling
to participate fully or attend for follow up, children under 1 year of age and perforated
ulcers
Male (74%), aged 50 to 75 years (26%)
Interventions 0.2% chlorhexidine gluconate drops prepared from 20% solution compared to 2.5%
natamycin
Source of natamycin from the EITC Chittagong. Both drops were given one drop hourly
for first 3 hours, then hourly for 2 days, 2 hourly for 5 days, and 3 hourly for 2 weeks - a
total of three weeks. No improvement at 5 days was assessed as treatment failure. Rescue
drugs were given
Outcomes Healing at 21 days characterised as intact epithelium, with or without scar formation,
but no perforation, anterior staphyloma, no adherent leukoma, no fluorescein staining,
no hypopyon and improvement of vision or vision no worse than baseline
Divided analysis to smear positive and culture positive cases
Toxicity to drug and cataract were also assessed on long term follow-up
Notes This is a follow-up study done by Rahman. Chlorhexidine gluconate 0.2% was used
based on the previous study. Ulcers were graded based on size of ulcer. Classified severe if
size is greater than 6 mm. Aspergillus and Fusarium were the two most common etiology
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The randomization of individuals was com-
puter generated in London....” Page 920
Allocation concealment (selection bias) Low risk “... and the codes for the alternative treat-
ments sealed in serially numbered opaque en-
velopes, which were opened in sequence by
the research ophthalmologist as the trial pro-
gressed.” Page 920
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “It was not possible to mask the ophthalmol-
ogist or nurses to the medications because of
their different appearances” Page 920
Blinding of participants not stated directly
but can be inferred that they were masked
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Rahman 1998 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “It was not possible to mask the ophthalmol-
ogist or nurses to the medications because of
their different appearances” Page 920
Incomplete outcome data (attrition bias)
All outcomes
High risk 13/35 of chlorhexidine 0.2% group
dropped out of the study by 21 days com-
pared to 3/36 of the natamycin 2.5%
group. Page 921, figure 1
Selective reporting (reporting bias) Unclear risk Main outcome was healing at 21 days of
treatment but other follow-up periods also
available and not clear that this outcome
was pre-specified or not
BID: twice-daily dose
KOH: potassium hydroxide
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Jones 1975 This is a lecture on the principles in the management of keratomycosis
Kalavathy 2002 The article is a commentary to Agarwal 2001
Kalavathy 2005 This is not a RCT. The first fifty consecutive patients received natamycin while the next fifty patients were given
itraconazole
Lavingia 1986 This is an in vitro study on antifungal properties of amphotericin B
Mabon 1998 The article is not a RCT but an overview on fungal keratitis
Mahashabde 1987 This is a case series
Maichuk 1990 This is a case series using antifungal agents for different ocular fungal infections
Maichuk 1991 This is a case series using antifungal agents for different ocular fungal infections
Maichuk 1994 This is a case series using antifungal agents for different ocular fungal infections
Maichuk 1995 This is a case series
Martin 1996 The article is an in vitro study
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(Continued)
Mitsui 1987 This is a case series
Panda 1996 It is not a RCT. Six consecutive eyes were treated with topical fluconazole
Rao 1997 It is a commentary to another article
Ray 2002 The article is a another commentary to Agarwal 2001
Sun 1996 There was attempt at randomisation. There was no mention of centralised randomisation. Masking of patients
was impossible due to different form of the medication given. Masking of care givers and outcome assessors
was not reported although difficult to perform because the treatments are in different forms (suspension and oil
mixture). There was also no report on drop out rates
Xie 2001 This is a retrospective study on severe fungal ulcers which needed penetrating keratoplasty
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT00516399
Trial name or title A Clinical Trial of the Treatment of Fungal Corneal Ulcers With Povidone-Iodine
Methods Randomised controlled trial
Participants People with fungal corneal ulcers
Interventions Povidone-iodine 1.25% ophthalmic solution compared to natamycin ophthalmic suspension, USP 5%
Outcomes Following text from entry on clinicaltrials.gov:
Number of days until disappearance of hypopyon and criteria for recovery and cure are met and subject is discharged
home. Number of treatment failures. Ocular complications from the infection and ocular and systemic complications
from the treatment. [ Time Frame: Inferior outcome is defined as cure time under povidone-iodine treatment, which
is at least 4 days longer than cure time under natamycin, or time until criteria for improvement to hospital discharge
is reached. ] [ Designated as safety issue: Yes ]
Starting date March 2008
Contact information Sherwin J Isenberg, M.D. isenberg@ucla.edu
Notes http://clinicaltrials.gov/ct2/show/NCT00516399
Trial as yet unpublished: completion date September 2011
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NCT00996736
Trial name or title Mycotic Ulcer Treatment Trial I (MUTT I)
Methods Randomised controlled trial
Participants People with corneal ulcer aged 16 years and older
Interventions Natamycin 5% compared to voriconazole 1%
Outcomes Following text from entry on clinicaltrials.gov:
Primary OutcomeMeasures: Best spectacle-corrected logMAR visual acuity [ TimeFrame: 3 months from enrollment
] [ Designated as safety issue: No ]The primary analysis is best spectacle-corrected logMAR visual acuity, correcting
for enrollment BSCVA and treatment arm in a multiple linear regression model. The pre-specified non-inferiority
margin is less than 1.5 lines logMAR acuity. (Adjusted three-month visual acuity confidence bounds for the difference
between the voriconazole and natamycin groups which meet or exceed 0.15 logMAR units would not permit
noninferiority to be declared.) Note that this design also allows declaration of superiority (2-sided alpha of 0.05,
corrected for an interim analysis)
Secondary OutcomeMeasures: Best spectacle-corrected logMAR visual acuity [ TimeFrame: 3 weeks after enrollment
] [Designated as safety issue: No ]Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting
for enrollment BSCVA and treatment arm in a multiple linear regression model
Best spectacle-corrected logMAR visual acuity only in Indian sites [ Time Frame: 3 weeks and 3 months after
enrollment ] [ Designated as safety issue: No ]Best spectacle-corrected logMAR visual acuity only in Indian sites, 3
weeks and 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear
regression model
Hard contact-lens corrected visual acuity measured in logMAR [ Time Frame: 3 months after enrollment ] [
Designated as safety issue: No ]Hard contact-lens corrected visual acuity measured in logMAR 3 months after
enrollment
Size of infiltrate/scar [ Time Frame: 3 weeks and 3 months after enrollment ] [ Designated as safety issue: No ]Size
of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate
Time to resolution of epithelial defect [ Time Frame: At the time of resolution of epithelial defect ] [ Designated as
safety issue: No ]Time to resolution of epithelial defect
Number of perforations and other adverse events [ Time Frame: At the time of perforation/adverse event ] [Designated
as safety issue: No ]
Minimum inhibitory concentration of isolates [ Time Frame: 3 months after enrollment ] [ Designated as safety
issue: No ]
Microbiological cure at 7 days [ Time Frame: 7 days after enrollment ] [ Designated as safety issue: No ]
Starting date April 2010
Contact information Tom Lietman, MD tom.lietman@ucsf.edu
Notes http://clinicaltrials.gov/ct2/show/NCT00996736
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NCT00997035
Trial name or title Mycotic Ulcer Treatment Trial II (MUTT II)
Methods Randomised controlled trial
Participants People aged 16 years or older with fungal corneal ulcer
Interventions Topical voriconazole 1% combined with oral voriconazole compared to topical voriconazole 1% alone
Outcomes Following text from entry on clinicaltrials.gov:
Primary Outcome Measures: Rate of perforation [ Time Frame: 3 months from enrollment ] [ Designated as
safety issue: No ]Comparison of rate of perforation between the treatment groups (topical voriconazole with oral
voriconazole vs. topical voriconazole with oral placebo)
Secondary OutcomeMeasures: Best spectacle-corrected logMAR visual acuity [ TimeFrame: 3 weeks after enrollment
] [Designated as safety issue: No ]Best spectacle-corrected logMAR visual acuity at 3 weeks after enrollment, adjusting
for enrollment BSCVA and treatment arm in a multiple linear
Best spectacle-corrected logMAR visual acuity only in Indian sites [ Time Frame: 3 weeks and 3 months after
enrollment ] [ Designated as safety issue: No ]Best spectacle-corrected logMAR visual acuity only in Indian sites, 3
weeks and 3 months after enrollment, adjusting for enrollment BSCVA and treatment arm in a multiple linear
regression model
Best spectacle-corrected logMAR visual acuity [ Time Frame: 3 months after enrollment ] [ Designated as safety issue:
No ]Best spectacle-corrected logMAR visual acuity 3 months after enrollment, adjusting for enrollment BSCVA and
treatment arm in a multiple linear
Hard contact-lens corrected visual acuity measured in logMAR [ Time Frame: 3 months after enrollment ] [
Designated as safety issue: No ]Hard contact-lens corrected visual acuity measured in logMAR 3 months after
enrollment
Size of infiltrate/scar [ Time Frame: 3 weeks and 3 months after enrollment ] [ Designated as safety issue: No ]Size
of infiltrate/scar at 3 weeks and 3 months after enrollment, using enrollment infiltrate scar/size as a covariate
Time to resolution of epithelial defect [ Time Frame: At the time of resolution of epithelial defect ] [ Designated as
safety issue: No ]
Number of adverse events [ Time Frame: At the time of adverse event ] [ Designated as safety issue: No ]
Minimum inhibitory concentration of isolates [ Time Frame: 3 months after enrollment ] [ Designated as safety
issue: No ]
Microbiological cure at 7 days [ Time Frame: 7 days after enrollment ] [ Designated as safety issue: No ]
Starting date May 2010
Contact information Nisha Acharya, MD, MS nisha.acharya@ucsf.edu
Notes http://clinicaltrials.gov/ct2/show/NCT00997035
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D A T A A N D A N A L Y S E S
Comparison 1. 1% silver sulphadiazine versus 1% miconazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Ulcer healed at 2 to 4 weeks 2 70 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.25, 1.07]
Comparison 2. Chlorhexidine versus natamycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Favourable response at 5 days 2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.28, 0.77]
2 Ulcer healed at 21 days 2 110 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.55, 1.08]
Analysis 1.1. Comparison 1 1% silver sulphadiazine versus 1% miconazole, Outcome 1 Ulcer healed at 2 to 4
weeks.
Review: Medical interventions for fungal keratitis
Comparison: 1 1% silver sulphadiazine versus 1% miconazole
Outcome: 1 Ulcer healed at 2 to 4 weeks
Study or subgroup Silver sulphadiazine Miconazole
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Mohan 1987 15/20 6/10 37.2 % 0.63 [ 0.21, 1.83 ]
Mohan 1988 16/20 11/20 62.8 % 0.44 [ 0.16, 1.21 ]
Total (95% CI) 40 30 100.0 % 0.51 [ 0.25, 1.07 ]
Total events: 31 (Silver sulphadiazine), 17 (Miconazole)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.79 (P = 0.073)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours silver sulphadia Favours miconazole
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Analysis 2.1. Comparison 2 Chlorhexidine versus natamycin, Outcome 1 Favourable response at 5 days.
Review: Medical interventions for fungal keratitis
Comparison: 2 Chlorhexidine versus natamycin
Outcome: 1 Favourable response at 5 days
Study or subgroup Chlorhexidine Natamycin
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rahman 1997 24/42 7/16 43.4 % 0.76 [ 0.44, 1.33 ]
Rahman 1998 31/35 18/35 56.6 % 0.24 [ 0.09, 0.63 ]
Total (95% CI) 77 51 100.0 % 0.46 [ 0.28, 0.77 ]
Total events: 55 (Chlorhexidine), 25 (Natamycin)
Heterogeneity: Chi2 = 4.90, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 3.00 (P = 0.0027)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours natamycin
Analysis 2.2. Comparison 2 Chlorhexidine versus natamycin, Outcome 2 Ulcer healed at 21 days.
Review: Medical interventions for fungal keratitis
Comparison: 2 Chlorhexidine versus natamycin
Outcome: 2 Ulcer healed at 21 days
Study or subgroup Chlorhexidine Natamycin
Risk
Ratio(Non-
event) Weight
Risk
Ratio(Non-
event)
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rahman 1997 20/32 7/14 29.7 % 0.75 [ 0.38, 1.49 ]
Rahman 1998 14/32 9/32 70.3 % 0.78 [ 0.54, 1.14 ]
Total (95% CI) 64 46 100.0 % 0.77 [ 0.55, 1.08 ]
Total events: 34 (Chlorhexidine), 16 (Natamycin)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours chlorhexidine Favours natamycin
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A D D I T I O N A L T A B L E S
Table 1. Anti-fungal agents studied in the included trials
Study Intervention Dose Treatment dura-
tion
Intervention Dose Treatment dura-
tion
Agarwal 2001 Topical itracona-
zole
1%, every hour For 6 weeks after
keratitis resolved
Oral Itraconazole
Topical itracona-
zole
100 mg twice
daily
1%, every hour
3 weeks
For 6 weeks after
keratitis resolved
Arora 2011 Topical
natamycin
5%, every hour Two weeks
“Further
dosage titrated ac-
cording to the pa-
tient’s response”
Topical
voriconazole
1%. every hour Two weeks
“Further
dosage titrated ac-
cording to the pa-
tient’s response”
Mahdy 2010 Topical ampho-
tericin B
Subconjunc-
tival injection of
fluconazole
0.05%, every two
hours
0.5 ml of 2 mg/
ml, daily
?
20 in-
jections, first 10
every day, second
10 every two days
Topical ampho-
tericin B
0.05%, every two
hours
?
Mohan 1987 Topical silver sul-
phadiazine
Two doses stud-
ied: 0.5% and
1%, applied 5
times a day
? Topical micona-
zole
1%, applied 5
times a day
?
Mohan 1988 Topical silver sul-
phadiazine
1%, applied 5
times a day
If no im-
provement after
1 week, switched
to other treat-
ment, treatment
continued for 2
weeks after clini-
cal healing of ul-
cer
Topical micona-
zole
1%, applied 5
times a day
If no im-
provement after
1 week, switched
to other treat-
ment, treatment
continued for 2
weeks after clini-
cal healing of ul-
cer
Prajna 2003 Topical
natamycin
5%, every hour
between7amand
9pm
Four weeks Topical
econazole
2%, every hour
between7amand
9pm
Four weeks
Prajna 2010* Topical
natamycin
5%, every hour
while awake
Ev-
ery hour for one
week followed by
every two hours
Topical
voriconazole
1%, every hour
while awake
Ev-
ery hour for one
week followed by
every two hours
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Table 1. Anti-fungal agents studied in the included trials (Continued)
for two weeks,
further continua-
tion at discretion
of physician
for two weeks,
further continua-
tion at discretion
of physician
Rahman 1997 Topical
natamycin
5% Day 1: Half-
hourly for three
hours, hourly
during
waking hours for
rest of dayDays 2
to 5: 2-hourly
Then
3-hourly for a
further 2 weeks.
If no improve-
ment at 5 days
swopped to an-
other treatment
Topi-
cal chlorhexidine
gluconate
Three doses stud-
ied: 0.05%, 0.
1% and 0.2%
Day 1: Half-
hourly for three
hours, hourly
during
waking hours for
rest of dayDays 2
to 5: 2-hourly
Then 3-
hourly for a fur-
ther 2 weeksIf no
improvement at
5 days swopped
to another treat-
ment
Rahman 1998 Topical
natamycin
2.5% Half-hourly for
first 3 hours, then
1 hourly for 2
days, 2
hourly for 5 days,
and 3 hourly for
3 weeks. If no
improvement at
5 days treatment
changed
Topi-
cal chlorhexidine
gluconate
0.2% Half-hourly for
first 3 hours, then
1 hourly for 2
days, 2
hourly for 5 days,
and 3 hourly for
3 weeks. If no
improvement at
5 days treatment
changed
* Participants were also randomized to “scraping of the corneal epithelium”
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Eye Infections, Fungal
#2 MeSH descriptor Keratitis
#3 fung* near keratit*
#4 fung* near infect* near eye*
#5 fung* near infect* near ocular
#6 keratomycosis
#7 keratomicosis
#8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)
#9 MeSH descriptor Antifungal Agents
#10 MeSH descriptor Natamycin
#11 natamycin*
#12 MeSH descriptor Chlorhexidine
#13 chlorhexidine*
#14 MeSH descriptor Econazole
#15 econazole*
#16 MeSH descriptor Itraconazole
#17 itraconazole*
#18 MeSH descriptor Miconazole
#19 miconazole*
#20 anti fung*
#21 antifung*
#22 (#9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#8 AND #22)
Appendix 2. MEDLINE (OVID) search strategy
1 randomized controlled trial.pt.
2 (randomized or randomised).ab,ti.
3 placebo.ab,ti.
4 dt.fs.
5 randomly.ab,ti.
6 trial.ab,ti.
7 groups.ab,ti.
8 or/1-7
9 exp animals/
10 exp humans/
11 9 not (9 and 10)
12 8 not 11
13 exp eye infections, fungal/
14 exp keratitis/
15 (fung$ adj2 keratit$).tw.
16 (fung$ adj3 infect$ adj3 eye$).tw.
17 (fung$ adj3 infect$ adj3 ocular).tw.
18 keratom?cosis.tw.
19 or/13-18
20 exp antifungal agents/
21 exp natamycin/
22 natamycin$.tw.
23 exp chlorhexidine/
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24 chlorhexidine$.tw.
25 exp econazole/
26 econazole$.tw.
27 exp itraconazole/
28 itraconazole$.tw.
29 exp miconazole/
30 miconazole$.tw.
31 antifung$.tw.
32 anti fung$.tw.
33 or/20-32
34 19 and 33
35 12 and 34
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE (OVID) search strategy
1 exp randomized controlled trial/
2 exp randomization/
3 exp double blind procedure/
4 exp single blind procedure/
5 random$.tw.
6 or/1-5
7 (animal or animal experiment).sh.
8 human.sh.
9 7 and 8
10 7 not 9
11 6 not 10
12 exp clinical trial/
13 (clin$ adj3 trial$).tw.
14 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15 exp placebo/
16 placebo$.tw.
17 random$.tw.
18 exp experimental design/
19 exp crossover procedure/
20 exp control group/
21 exp latin square design/
22 or/12-21
23 22 not 10
24 23 not 11
25 exp comparative study/
26 exp evaluation/
27 exp prospective study/
28 (control$ or prospectiv$ or volunteer$).tw.
29 or/25-28
30 29 not 10 (930488)
31 30 not (11 or 23)
32 11 or 24 or 31
33 exp keratomycosis/
34 exp keratitis/
35 (fung$ adj2 keratit$).tw.
36 (fung$ adj3 infect$ adj3 eye$).tw.
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37 (fung$ adj3 infect$ adj3 ocular).tw.
38 keratom?cosis.tw.
39 or/33-38
40 exp antifungal agent/
41 exp natamycin/
42 natamycin$.tw.
43 exp chlorhexidine/
44 chlorhexidine$.tw.
45 exp econazole/
46 econazole$.tw.
47 exp itraconazole/
48 itraconazole$.tw.
49 exp miconazole/
50 miconazole$.tw.
51 antifung$.tw.
52 anti fung$.tw.
53 or/40-52
54 39 and 53
55 32 and 54
Appendix 4. LILACS search strategy
eye$ or ocular and fungal keratitis or keratomycosis
Appendix 5. metaRegister of Controlled Trials search strategy
fungal keratitis
Appendix 6. ClinicalTrials. gov search strategy
fungal keratitis
WH A T ’ S N E W
Last assessed as up-to-date: 29 August 2011.
Date Event Description
15 December 2011 New citation required but conclusions have not
changed
Issue 2, 2012: Three new trials were included in the
update (Arora 2011; Mahdy 2010; Prajna 2010).
15 December 2011 New search has been performed Issue 2, 2012: Electronic searches were updated, risk of
bias tables have been completed for all included trials
and text modified. A new author joined the review
team to help with updating the review
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H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 1, 2008
Date Event Description
22 October 2008 Amended Converted to new review format.
13 November 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
NVF conceived the review question, co-ordinated the review, organised retrieval of full text copies, wrote to authors of papers for
additional information, provided additional data about papers, obtained and screened data on unpublished studies, analysed and
interpreted data, performed previous work that was the foundation of the review and wrote the review.
NVF and IP screened initial search results, screened retrieved papers against inclusion criteria, extracted and entered data in to RevMan.
Update Issue 2, 2012
NVF and JE screened search results, appraised quality of papers, extracted and entered data in to RevMan and wrote the update.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• NIHR/Department of Health, UK.
Funded JE to assist in updating the version published in Issue 2, 2012.
External sources
• No sources of support supplied
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antifungal Agents [∗therapeutic use]; Eye Infections, Fungal [∗drug therapy]; Keratitis [∗drug therapy; microbiology]; Randomized
Controlled Trials as Topic
MeSH check words
Humans
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